Sarah Duncan Acquires 5,522 Shares of NIOX Group (LON:NIOX) Stock

NIOX Group Plc (LON:NIOX) insider Sarah Duncan bought 5,522 shares of NIOX Group stock in a transaction dated Wednesday, December 3rd. The stock was acquired at an average cost of GBX 71 per share, for a total transaction of £3,920.62.

NIOX Group Trading Down 1.7%

NIOX stock opened at GBX 70.20 on Friday. The business has a fifty day moving average price of GBX 71.22 and a 200 day moving average price of GBX 69.97. The company has a debt-to-equity ratio of 1.10, a current ratio of 6.31 and a quick ratio of 1.94. NIOX Group Plc has a fifty-two week low of GBX 53.40 and a fifty-two week high of GBX 77.60. The stock has a market capitalization of £293.35 million, a price-to-earnings ratio of 56.16 and a beta of 0.92.

NIOX Group (LON:NIOX) last posted its quarterly earnings data on Tuesday, September 30th. The company reported GBX 1.43 EPS for the quarter. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%. Analysts expect that NIOX Group Plc will post 1.1658256 EPS for the current fiscal year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.